Prosecution Insights
Last updated: October 04, 2026

Jc One World

Technology area: Biotechnology & Pharmaceuticals

9 pending office actions • 7 clients • 8 examiners • 6 art units • 0 of 9 (0%) have an AI response strategy ready • 30 patents granted in the last 365 days

Analysis

JC ONE WORLD has managed 177 career applications in the Biotechnology & Pharmaceuticals technology area. The firm currently has 9 pending office actions and a resolved allowance rate pct of 95.65.

Prosecution at the firm involves an avg office actions per allowance of 1.36. This 1.36 figure provides a basis for practitioners to anticipate the number of examiner interactions required in the Biotechnology & Pharmaceuticals sector. The 95.65 resolved allowance rate pct reflects the proportion of cases that reached allowance relative to the 177 career applications. The 9 pending office actions represent the current cases awaiting a USPTO response.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=177 apps, methodology: how we score firms)

95.6%
Allowance Rate
n=177
+0.66σ
Allowance Rate (norm)
n=177
1.4
OAs to Allowance
n=44
-1.28σ
OAs to Allow (norm)
n=44
718 days
Time to Allowance
n=44
+5.9pp
Interview Lift
n=177
10.9%
RCE Rate
n=177
0.0%
Appeal Rate
n=177

Rejection Performance (% of received rejections ultimately overcome)

—
§101 Overcome
n=14 (min 20)
—
§102 Overcome
n=13 (min 20)
—
§103 Overcome
n=19 (min 20)
53.8%
§112 Overcome
n=26

Specialization & Scale

A61K, A61P, C12N
Top CPC Subclasses
26%
Top-3 CPC Share
n=177
0
Practitioners
n=177
—
Apps / Practitioner
n=177 (min 20)

Portfolio Summary

9
Total Pending OAs
9
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

7
Hard (78%)
1
Medium (11%)
1
Easy (11%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only1 (11%)
§101 + other4 (44%)
§103 only1 (11%)
§112 only1 (11%)
Multi-statute (no §101)2 (22%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
56% of docket
0
Information Tech
0% of docket
1
Communications
11% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
11% of docket
2
Business / Other
22% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TATGE, LEXUS MARC 2 50.0% +100.0%
TORRICO-LOPEZ, ALAN 1 29.1% +37.8%
DAGNEW, MEKONNEN D 1 83.5% +15.4%
AUDET, MAURY A 1 50.1% +23.9%
ABBOTT, KODYE LEE 1 53.1% +71.4%
PETRASH, HILARY ANN 1 64.5% +51.7%
BATES, KEENAN ALEXANDER 1 45.5% +79.5%
HANEY, AMANDA MARIE 1 36.4% +44.9%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
19001419 METHOD OF DETECTING A DEFOCUS OF AN IMAGE SENSOR AND IMAGE SENSOR DAGNEW, MEKONNEN D —

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18834230 METHOD FOR GRADING SUITABLE CONSTRUCTION RANGE BASED ON COLD ISLAND VALUE EVALUATION TORRICO-LOPEZ, ALAN —
18650037 USE OF PROTEIN SEQUENCE CAPABLE OF BINDING TO SUBSTRATE IN PREPARATION OF PRODUCT FOR INHIBITING FIBRIN ASSEMBLY AUDET, MAURY A —
18592249 APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS ABBOTT, KODYE LEE —
18415188 COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA PETRASH, HILARY ANN —
18374236 GENE CIRCUIT, RNA DELIVERY SYSTEM AND USE THEREOF TATGE, LEXUS MARC —
18373605 NUCLEIC ACID DELIVERY SYSTEM AND APPLICATION THEREOF TATGE, LEXUS MARC —
18271654 COMPOSITIONS AND METHODS FOR INSTANT NUCLEIC ACID DETECTION HANEY, AMANDA MARIE —

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18834230 METHOD FOR GRADING SUITABLE CONSTRUCTION RANGE BASED ON COLD ISLAND VALUE EVALUATION TORRICO-LOPEZ, ALAN —
19001419 METHOD OF DETECTING A DEFOCUS OF AN IMAGE SENSOR AND IMAGE SENSOR DAGNEW, MEKONNEN D —
18650037 USE OF PROTEIN SEQUENCE CAPABLE OF BINDING TO SUBSTRATE IN PREPARATION OF PRODUCT FOR INHIBITING FIBRIN ASSEMBLY AUDET, MAURY A —
18592249 APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS ABBOTT, KODYE LEE —
18415188 COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA PETRASH, HILARY ANN —
18521956 METHOD FOR DIFFERENTIATING HUMAN INDUCED PLURIPOTENT STEM CELLS INTO OLIGODENDROCYTES, AND KIT AND USE BATES, KEENAN ALEXANDER —
18374236 GENE CIRCUIT, RNA DELIVERY SYSTEM AND USE THEREOF TATGE, LEXUS MARC —
18373605 NUCLEIC ACID DELIVERY SYSTEM AND APPLICATION THEREOF TATGE, LEXUS MARC —

Client Portfolio (7 clients)

Top Art Units

Art UnitApps
16372
36251
26381
16341
16311
16821

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18834230 METHOD FOR GRADING SUITABLE CONSTRUCTION RANGE BASED ON COLD ISLAND VALUE EVALUATION Architecs & Engineers Co., Ltd. Of Southeast University TORRICO-LOPEZ, ALAN 3625 §101 Non-Final OA — Pending Sep 18, 2025
19001419 METHOD OF DETECTING A DEFOCUS OF AN IMAGE SENSOR AND IMAGE SENSOR Omnivision Technologies, Inc. DAGNEW, MEKONNEN D 2638 §103 Non-Final OA — Pending Dec 25, 2024
18650037 USE OF PROTEIN SEQUENCE CAPABLE OF BINDING TO SUBSTRATE IN PREPARATION OF PRODUCT FOR INHIBITING FIBRIN ASSEMBLY Huazhong Agricultural University AUDET, MAURY A §101§112 Non-Final OA — Pending Apr 29, 2024
18592249 APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS Allife Medicine (Beijing) Limited ABBOTT, KODYE LEE 1634 §103§112 Non-Final OA — Pending Feb 29, 2024
18415188 COMPOSITIONS AND METHODS FOR TREATING ACUTE MYELOID LEUKEMIA Wuhan University PETRASH, HILARY ANN §101§102§103§112 Non-Final OA — Pending Jan 17, 2024
18521956 METHOD FOR DIFFERENTIATING HUMAN INDUCED PLURIPOTENT STEM CELLS INTO OLIGODENDROCYTES, AND KIT AND USE Allife Medicine (Zhuhai) Limited BATES, KEENAN ALEXANDER 1631 §112 Non-Final OA — Pending Nov 28, 2023
18374236 GENE CIRCUIT, RNA DELIVERY SYSTEM AND USE THEREOF Nanjing University TATGE, LEXUS MARC 1637 §101§102§112DP Non-Final OA — Pending Sep 28, 2023
18373605 NUCLEIC ACID DELIVERY SYSTEM AND APPLICATION THEREOF Nanjing University TATGE, LEXUS MARC 1637 §101§102§103§112DP Non-Final OA — Pending Sep 27, 2023
18271654 COMPOSITIONS AND METHODS FOR INSTANT NUCLEIC ACID DETECTION Wuhan University HANEY, AMANDA MARIE 1682 §102§103§112 Non-Final OA — Pending Jul 10, 2023

Managing Jc One World's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month